Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Vroom Inc Q4 Financial Results Impact Stock Performance and Future Outlook

Elaine Mendonca by Elaine Mendonca
March 13, 2024
in Breaking News
0
Automotive Trading online
0
SHARES
11
VIEWS
Share on FacebookShare on Twitter

Vroom Inc. released its Q4 financial results on March 13, 2024, impacting its stock performance significantly. Here is a breakdown of the latest information:

Financial Performance:
– Vroom incurred a loss of $141.3 million in Q4, equivalent to $80.51 per share.
– Quarterly sales reached $235.92 million, exceeding the analyst consensus of $232 million.
– The company is in the process of winding down its e-commerce and used vehicle dealership operations, with plans to complete this transition by the end of Q1 2024.

Stock Performance:
– Following the earnings report, Vroom shares initially surged by 53.8% but later dropped by 11.2% after hours, closing at $17.49 and falling to $15.52 respectively.

Analyst Expectations:
– Analysts had predicted losses per share of $29.600 for Q4, with expected revenue of $232.0 million, showing growth from the previous year.

Future Outlook:
– Vroom’s shift away from e-commerce towards maximizing stakeholder value through businesses like United Auto Credit and CarStory reflects a change in focus for the company.
– These financial results and strategic decisions are shaping Vroom’s stock performance and future direction as it adapts to changes in its operations.

Vroom Inc. (VRM) Stock Price Soars 53.83% on March 13, 2024, But Faces After-Hours Volatility

On March 13, 2024, Vroom Inc. (VRM) experienced a significant increase in its stock price, closing at $17.49. This represented a $6.12 increase from the previous market close, marking a substantial 53.83% rise in value. However, despite this impressive gain, VRM is still trading near the bottom of its 52-week range and below its 200-day simple moving average.

After the market closed, VRM’s stock price dropped by $2.88 in after-hours trading, indicating some volatility and uncertainty surrounding the company’s performance. This sudden drop may have been influenced by various factors such as market conditions, investor sentiment, or company-specific news.

VRM Stock Performance Analysis: Mixed Results Revealed on March 13, 2024

On March 13, 2024, VRM stock experienced mixed performances based on the financial data provided by CNN Money. The company’s total revenue for the past year was reported at $1.95 billion, which marked a significant decrease of 38.8% compared to the previous year. However, there was a slight increase of 4.64% in total revenue since the last quarter, indicating some positive momentum in the company’s financial performance.

In terms of net income, VRM reported a net loss of $451.91 million for the past year, representing a decrease of 21.84% compared to the previous year. The net loss for the third quarter was reported at $82.86 million, showing a further decrease of 24.94% since the last quarter. These figures suggest that VRM is facing challenges in generating profits and managing its expenses effectively.

Furthermore, the earnings per share (EPS) for VRM was reported at -$262.15 for the past year, indicating a decrease of 20.53% compared to the previous year. The EPS for the third quarter was reported at -$47.45, marking a decrease of 24.45% since the last quarter. This decline in EPS reflects the company’s struggle to improve its profitability and create value for its shareholders.

Overall, the financial data for VRM on March 13, 2024, paints a mixed picture of the company’s performance. While there was a slight improvement in total revenue since the last quarter, the significant decreases in net income and EPS highlight the challenges that VRM is currently facing. Investors and analysts will be closely monitoring the company’s future financial reports to assess its ability to overcome these challenges and drive sustainable growth in the long term.

Tags: VRM
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Biotechnology Trading online

Spruce Biosciences Reports Improved Financial Performance and Strategic CostCutting Measures for FY23

Quoin Pharmaceuticals Exceeds Q4 Earnings Expectations

Empowering Remote Regions: the Nano Grid Technology for Reliable Electricity Solutions

FTC Solar Reports Mixed Q4 Financial Results with Focus on Future Growth

Recommended

Camping World Stock

Can Camping World Maintain Its Dividend Amid Market Pressures?

5 months ago
Trinity Biotech Stock

Trinity Biotech Faces Critical Nasdaq Compliance Deadline

5 months ago
DVY stock news

Amarin Strengthens Position and Maximizes Shareholder Value Through Share Repurchase Agreement with Cantor Fitzgerald

2 years ago
ASTeMobile Stock

ASTeMobile Shares Face Mounting Pressure as Investor Confidence Wanes

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Trending

Cassava Sciences Stock
Analysis

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

by Jackson Burston
February 8, 2026
0

The future of Cassava Sciences appears uncertain following the definitive termination of its Alzheimer's disease program. Detailed...

DroneShield Stock

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Rock Tech Lithium Stock

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays
  • DroneShield Shares Face Headwinds Despite Record Performance
  • Rock Tech Lithium: Investors Await the Final Go-Ahead

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com